These data show that camizestrant promotes selective and proteasome-mediated ER degradation, completely suppresses transcription by fully antagonizing residual ER, and impairs proliferation in ER+ breast cancer cell lines, without agonizing ER in uterine models, in marked contrast with AZD9496. Here, ESR1 is linked to breast cancer.